Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has announced the appointment of Dr Colin Biggin as Head of Quality.
Dr Biggin has over 15 years’ experience in radiochemistry and radiopharmaceutical development. His most recent full-time role was with Algeta where he worked in multiple roles from 2006 and through the acquisition of Algeta by Bayer in 2014, before leaving his position of Director of Radiation Protection in 2015.
At Algeta, Dr Biggin was among the earliest recruits to the company and was responsible for providing scientific and project support across all departments with broad expertise in Regulatory and Quality Assurance, Quality Control, Research and Clinical Development, Manufacturing and Commercial.
"He was significantly involved in the highly successful launch of Xofigo, Algeta’s lead radiopharmaceutical product targeting metastatic prostate cancer, in the USA," said the company in a statement.
Since 2015, Dr Biggin has been consulting to international radiopharmaceutical companies in the US, Europe and Australia.
According to Dr Biggin, “Joining an innovative company like Clarity has many similarities to joining the 10 person team at Algeta in 2006, including the size of the company, the stage of clinical development, and the massive potential for the lead products. I am delighted to be working with the highly skilled team at Clarity to develop safer and more effective medicines to improve patient outcomes”.
Clarity’s Executive Chairman, Dr Alan Taylor, said: “We are very excited to welcome Dr Biggin to our team and are looking forward to leveraging his expertise in Quality systems, R&D and clinical development. As Clarity enters a number of clinical trials and transitions from a start-up into a mature radiopharmaceutical company, it is crucial for us to ensure high quality operations and R&D activities during every stage of radiopharmaceutical development. We believe that the experience Dr Biggin gained while working at Algeta will prove invaluable to Clarity as we progress our products through clinical development.”
Dr Biggin holds a B.Sc (Honours) in Environmental Biogeochemistry and a Ph.D. from the University of Glasgow. He is also a Charter Chemist and member of the Royal Society of Chemistry, the Society of Nuclear Medicine and Medical Imaging and the Health Physics Society.